OpenAI acquires Orchestra Bio to build on its life sciences tools

OpenAI announced on Oct. 20 that it had acquired Orchestra Bio, and Orchestra confirmed it is joining the company. OpenAI describes the startup as a platform that helps biopharma teams coordinate drug development.

Orchestra describes its work as spanning discovery, preclinical, manufacturing and clinical stages. It says AI agents can handle planning, orchestration and analysis while scientists and program leaders focus on decisions requiring their expertise. According to Axios, the platform lets scientists delegate tasks such as monitoring studies, tracking drug-development timelines and identifying potential delays to AI agents.

Madison Mills reports for Axios that OpenAI plans to integrate Orchestra’s team and technology into Rosalind, its suite of AI models and tools for life sciences researchers. Axios says financial terms of the acquisition were not disclosed. OpenAI says it aims to streamline drug-development operations and help new treatments reach patients sooner. Faster delivery is the company’s goal, not a reported result of the acquisition.